Spero Therapeutics (SPRO) Competitors $2.30 -0.02 (-0.86%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.31 +0.01 (+0.61%) As of 08/1/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SPRO vs. OPT, PGEN, SLDB, TERN, TRML, PRTC, SIGA, RZLT, CGEM, and KMDAShould you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Opthea (OPT), Precigen (PGEN), Solid Biosciences (SLDB), Terns Pharmaceuticals (TERN), Tourmaline Bio (TRML), PureTech Health (PRTC), Siga Technologies (SIGA), Rezolute (RZLT), Cullinan Therapeutics (CGEM), and Kamada (KMDA). These companies are all part of the "pharmaceutical products" industry. Spero Therapeutics vs. Its Competitors Opthea Precigen Solid Biosciences Terns Pharmaceuticals Tourmaline Bio PureTech Health Siga Technologies Rezolute Cullinan Therapeutics Kamada Spero Therapeutics (NASDAQ:SPRO) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings. Does the media refer more to SPRO or OPT? In the previous week, Spero Therapeutics had 1 more articles in the media than Opthea. MarketBeat recorded 1 mentions for Spero Therapeutics and 0 mentions for Opthea. Opthea's average media sentiment score of 0.67 beat Spero Therapeutics' score of 0.00 indicating that Opthea is being referred to more favorably in the news media. Company Overall Sentiment Spero Therapeutics Neutral Opthea Positive Which has stronger valuation and earnings, SPRO or OPT? Spero Therapeutics has higher revenue and earnings than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpero Therapeutics$47.98M2.68-$68.57M-$1.28-1.80Opthea$120K4,373.61-$220.24MN/AN/A Which has more risk and volatility, SPRO or OPT? Spero Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, Opthea has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Do insiders & institutionals have more ownership in SPRO or OPT? 25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 56.0% of Opthea shares are owned by institutional investors. 5.5% of Spero Therapeutics shares are owned by insiders. Comparatively, 3.2% of Opthea shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts prefer SPRO or OPT? Spero Therapeutics currently has a consensus target price of $5.00, suggesting a potential upside of 117.39%. Opthea has a consensus target price of $1.33, suggesting a potential downside of 60.90%. Given Spero Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Spero Therapeutics is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17 Is SPRO or OPT more profitable? Opthea has a net margin of 0.00% compared to Spero Therapeutics' net margin of -156.48%. Opthea's return on equity of 0.00% beat Spero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spero Therapeutics-156.48% -123.50% -58.96% Opthea N/A N/A N/A SummarySpero Therapeutics beats Opthea on 8 of the 15 factors compared between the two stocks. Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRO vs. The Competition Export to ExcelMetricSpero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$129.71M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-1.8017.6228.6723.80Price / Sales2.68179.18373.9066.58Price / CashN/A41.9535.4557.96Price / Book2.718.508.275.55Net Income-$68.57M-$55.06M$3.24B$259.03M7 Day Performance-1.29%-3.98%-3.69%-4.59%1 Month Performance-20.69%9.59%4.33%4.46%1 Year Performance75.57%6.72%25.95%18.03% Spero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPROSpero Therapeutics3.7349 of 5 stars$2.30-0.9%$5.00+117.4%+65.5%$129.71M$47.98M-1.80150Upcoming EarningsOPTOpthea0.3208 of 5 stars$3.41+7.2%$1.33-60.9%+53.2%$524.84M$120K0.008Gap UpPGENPrecigen3.9979 of 5 stars$1.83+4.0%$6.00+227.9%+16.8%$519.52M$3.92M-3.27190News CoveragePositive NewsOptions VolumeSLDBSolid Biosciences2.6741 of 5 stars$6.37-0.3%$15.10+137.0%-20.9%$495.32M$8.09M-2.13100Gap DownHigh Trading VolumeTERNTerns Pharmaceuticals3.5838 of 5 stars$5.64flat$15.63+177.0%-29.6%$492.58MN/A-5.1740Upcoming EarningsGap DownTRMLTourmaline Bio1.5803 of 5 stars$18.23-1.4%$49.33+170.6%+33.2%$474.67MN/A-5.6844Upcoming EarningsPRTCPureTech Health1.427 of 5 stars$18.56+0.3%$45.00+142.4%-12.1%$472.52M$4.83M0.00100Gap DownSIGASiga Technologies1.8634 of 5 stars$6.85+3.6%N/A-30.1%$472.23M$138.72M10.2240Upcoming EarningsRZLTRezolute2.3609 of 5 stars$5.38-0.2%$11.83+120.0%+33.1%$468.91MN/A-4.6840CGEMCullinan Therapeutics1.6 of 5 stars$7.52-0.1%$30.00+298.9%-59.1%$444.38MN/A-2.5830News CoverageUpcoming EarningsKMDAKamada4.488 of 5 stars$7.80+4.7%$13.00+66.7%+30.3%$428.41M$160.95M26.90360News CoverageGap Up Related Companies and Tools Related Companies Opthea Alternatives Precigen Alternatives Solid Biosciences Alternatives Terns Pharmaceuticals Alternatives Tourmaline Bio Alternatives PureTech Health Alternatives Siga Technologies Alternatives Rezolute Alternatives Cullinan Therapeutics Alternatives Kamada Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPRO Stock Alerts